RECRUITINGPhase 1 / Phase 2INTERVENTIONAL

Atomoxetine and DAW2022 on OSA Severity

Effect of Atomoxetine and DAW2022 on OSA Severity

About This Trial

Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. In previous research atomoxetine and oxybutynin showed promising effect at reducing OSA severity, however they reduced arousal threshold, one of the key traits responsible for OSA. Since oxybutynin was used mainly as a hypnotic, but it is burdened by several anti-cholinergic side effects, DAW2020, a hypnotic which prolonged the total sleep time in a previous trial in OSA patients, could be a better candidate to associate with atomoxetine.

Who May Be Eligible (Plain English)

Who May Qualify: - Moderate-to-severe OSA (AHI ≥ 15 events/hr) Who Should NOT Join This Trial: - All participants will be healthy and without major organ system disease that would preclude undergoing the physiological measurements. - Use of medications expected to stimulate or depress respiration (including opioids, barbiturates, acetazolamide, doxapram, almitrine, theophylline, 4-hydroxybutanoic acid). - Use of SNRIs/SSRIs. - Conditions likely to affect OSA physiology: neuromuscular disease or other major neurological disorder, heart failure (also below), or any other unstable major medical condition. - Sleep disordered breathing or respiratory disorders other than obstructive sleep apnea: - Other sleep disorders: periodic limb movements (periodic limb movement arousal index \> 10/hr), narcolepsy, or parasomnias. - Hypersensitivity to the study drug (angioedema or urticaria) - Contraindications to DAW2020 - Use of medications that lengthen QTc interval - Hypokaliemia, hypomagnesemia, uncontrolled thyroid disease - Severe claustrophobia. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Moderate-to-severe OSA (AHI ≥ 15 events/hr) Exclusion Criteria: * All participants will be healthy and without major organ system disease that would preclude undergoing the physiological measurements. * Use of medications expected to stimulate or depress respiration (including opioids, barbiturates, acetazolamide, doxapram, almitrine, theophylline, 4-hydroxybutanoic acid). * Use of SNRIs/SSRIs. * Conditions likely to affect OSA physiology: neuromuscular disease or other major neurological disorder, heart failure (also below), or any other unstable major medical condition. * Sleep disordered breathing or respiratory disorders other than obstructive sleep apnea: * Other sleep disorders: periodic limb movements (periodic limb movement arousal index \> 10/hr), narcolepsy, or parasomnias. * Hypersensitivity to the study drug (angioedema or urticaria) * Contraindications to DAW2020 * Use of medications that lengthen QTc interval * Hypokaliemia, hypomagnesemia, uncontrolled thyroid disease * Severe claustrophobia.

Treatments Being Tested

DRUG

Placebo oral capsule

Placebo pills for a week, 1 pill 4 hr before sleep and 1 pill 30 min before sleep

DRUG

Atomoxetine Oral Capsule [Strattera]

Atomoxetine for a week: 40 mg for 3 days 30 min before sleep, 80 mg for 4 days 30 min before sleep Simultaneous administration of DAW2020 for a week, 34 mg 4 h before sleep

Locations (1)

Brigham and Women's Hospital

Boston, Massachusetts, United States